Deerfield, Ill., November 8, 2019 – Lundbeck US, an affiliate of the global pharmaceutical company H. Lundbeck A/S, announced today it has been named a 2019 Top Workplace by the Chicago Tribune. This marks the second straight year that Lundbeck received the honor. Lundbeck was one of just 65 area employers recognized in the small-company category. The Top Workplace list is based solely on employee feedback and measures several aspects of workplace culture, including alignment and employees’ connection to the company.
“At Lundbeck, we have worked hard to build a patient-centric biopharmaceutical company,” says Peter Anastasiou, executive vice president and head of Lundbeck North America. “The fact that our own employees voted Lundbeck a Top Workplace is testament to the connectedness we all feel to our culture and purpose. I am so proud to receive this recognition, and I am grateful to our employees for sustaining our unique and meaningful culture.”
As the only global biopharmaceutical company solely focused the brain, Lundbeck is deeply committed to the communities we serve, and patient-centricity is at the heart of the corporate culture. Employees participate in hundreds of patient events each year, gaining deeper understanding of the challenges faced by people impacted by migraine, Parkinson’s disease, Alzheimer’s disease, and depression and other mental health disorders. Earlier this year, Lundbeck US was ranked #1 in corporate reputation by patient advocacy groups for the fourth straight year. This recognition is a point of pride for employees and a testament to the patient-first culture at Lundbeck.
Caring for people extends to our internal team as well and supporting the health and well-being of employees and their families is a high priority for the company. Lundbeck offers comprehensive health and welfare benefits, work-life programs, flexible work schedules, and a recognition program that includes peer-to-peer awards as well as quarterly and annual recognition. In addition, the company’s commitment to mental health starts within, and Lundbeck offers a variety of workplace programs geared toward reducing the stigma of mental illness and supporting employees’ mental health. For example, Lundbeck offers employees full access to the resources of Right Direction, an initiative it has supported nationwide that helps employers take on depression in the workplace.
Learn more about Lundbeck's unique culture in this Chicago Tribune profile.
Lundbeck is a global biopharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.
Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18.1 billion in 2018 (EUR 2.4 billion; USD 2.8 billion).
In the U.S., Lundbeck employs approximately 900 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in a broad range of initiatives each year that support our patient communities.
Lundbeck Media Contact:
Associate Director, Corporate Communications